Alteplase pulmonary embolism

Alteplase (rt-PA) +++ 50-60% ++/++ Bolus followed by infusions over 90 minutes weight-based dosing 2,750 Pulmonary embolism, stroke, clearance of an occluded arteriovenous catheter... 

Activase Alteplase, recombinant Genentech Acute myordial infarction, acute massive pulmonary embolism, ischemic stroke... 

Alteplase was the first commercially available recombinant tissue-type plasminogen activator (rt-PA) (25), It has a plasma half-life of less than five minutes and is metabolized by the liver, This agent was initially hailed as fibrin-specific unlike its precursors (urokinase and streptokinase). It was thought that this would result in a better safety profile, but this has not been born out in either the coronary or the peripheral experience, where actually there may be a higher bleeding risk as infusion time increases. Alteplase is currently indicated for use in the treatment of myocardial infarction, acute ischemic stroke, and pulmonary embolism. 

Therapeutic uses Currently alteplase is approved for the treatment of myocardial infarction, massive pulmonary embolism, and acute ischemic stroke. Alteplase seems to be superior to streptokinase and urokinase in dissolving older clots, and may ultimately be approved for other applications. Alteplase administered within 3 hours of the onset of ischemic stroke significantly improves clinical outcome, that is, the patients ability to perform activites of daily living. 

Alteplase (r-TPA) Activase (Genentech) Acute myocardial infarction pulmonary embolism stroke CVT clot removal... 

Alteplase aids in dissolution of blood clots. It is indicated in the lysis of thrombi in management of acute myocardial infarction (MI) or acute massive pulmonary embolism, and... 

Tissue plasminogen activator tPA alteplase (Activase) 59.04 Plasma volume (0.05 Lkg- ) 0.083 (initial) IV bolus injection followed by IV infusion (1.0 in both) Thrombolytic agent used in acute myocardial infarction, acute ischemic stroke and pulmonary embolism... 

---